IMRX
Price
$8.08
Change
+$0.08 (+1.00%)
Updated
Sep 26 closing price
Capitalization
510.97M
39 days until earnings call
NUVL
Price
$81.39
Change
+$3.87 (+4.99%)
Updated
Sep 26 closing price
Capitalization
5.87B
39 days until earnings call
Interact to see
Advertisement

IMRX vs NUVL

Header iconIMRX vs NUVL Comparison
Open Charts IMRX vs NUVLBanner chart's image
Immuneering
Price$8.08
Change+$0.08 (+1.00%)
Volume$6.01M
Capitalization510.97M
Nuvalent
Price$81.39
Change+$3.87 (+4.99%)
Volume$371.19K
Capitalization5.87B
IMRX vs NUVL Comparison Chart in %
Loading...
IMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMRX vs. NUVL commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMRX is a Hold and NUVL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (IMRX: $8.08 vs. NUVL: $81.39)
Brand notoriety: IMRX and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMRX: 390% vs. NUVL: 83%
Market capitalization -- IMRX: $510.97M vs. NUVL: $5.87B
IMRX [@Biotechnology] is valued at $510.97M. NUVL’s [@Biotechnology] market capitalization is $5.87B. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMRX’s FA Score shows that 0 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • IMRX’s FA Score: 0 green, 5 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than IMRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMRX’s TA Score shows that 4 TA indicator(s) are bullish while NUVL’s TA Score has 7 bullish TA indicator(s).

  • IMRX’s TA Score: 4 bullish, 6 bearish.
  • NUVL’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than IMRX.

Price Growth

IMRX (@Biotechnology) experienced а -12.74% price change this week, while NUVL (@Biotechnology) price change was +6.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

IMRX is expected to report earnings on Nov 06, 2025.

NUVL is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($5.87B) has a higher market cap than IMRX($511M). IMRX YTD gains are higher at: 267.273 vs. NUVL (3.973). IMRX has higher annual earnings (EBITDA): -63.7M vs. NUVL (-362.01M). NUVL has more cash in the bank: 1.01B vs. IMRX (26.4M). IMRX (0) and NUVL (0) have equivalent revenues.
IMRXNUVLIMRX / NUVL
Capitalization511M5.87B9%
EBITDA-63.7M-362.01M18%
Gain YTD267.2733.9736,727%
P/E RatioN/AN/A-
Revenue00-
Total Cash26.4M1.01B3%
Total Debt4MN/A-
TECHNICAL ANALYSIS
Technical Analysis
IMRXNUVL
RSI
ODDS (%)
Bearish Trend 3 days ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
88%
Bullish Trend 6 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
IMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RALIX10.670.09
+0.85%
Lazard Real Assets Instl
VYSZX6.120.05
+0.82%
Voya Small Company C
CSXCX51.310.28
+0.55%
Calvert US Large Cap Core Rspnb Idx C
FEVCX22.550.10
+0.45%
First Eagle US C
ARILX16.280.06
+0.37%
Aristotle Core Eq I

IMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMRX has been loosely correlated with SPRB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if IMRX jumps, then SPRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMRX
1D Price
Change %
IMRX100%
+1.00%
SPRB - IMRX
52%
Loosely correlated
N/A
NUVL - IMRX
32%
Poorly correlated
+4.99%
SRRK - IMRX
31%
Poorly correlated
+12.35%
ENTBF - IMRX
31%
Poorly correlated
-9.76%
TERN - IMRX
31%
Poorly correlated
+2.69%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XENE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+4.99%
XENE - NUVL
61%
Loosely correlated
+4.00%
CGON - NUVL
58%
Loosely correlated
+2.91%
RVMD - NUVL
57%
Loosely correlated
+3.32%
XNCR - NUVL
57%
Loosely correlated
+12.00%
IDYA - NUVL
57%
Loosely correlated
+4.44%
More